DDI2 and breast adenocarcinoma: Recently, it was shown that DDI2-deficient or protease-dead DDI2 mutant MDA-MB231 human breast adenocarcinoma cells are more sensitive to carfilzomib-induced apoptosis [85], suggesting that DDI2 is significant to the bounce-back response.